source
- Recon: Sino, Boehringer ink cancer drug deal worth $7B; CVS to split pharmacy business from insuranceWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 5d ago↗ source
- Boehringer Ingelheim strikes $7.4 billion deal with Sino Biopharma for preclinical ADC and TCE programsBoehringer Ingelheim announced a major licensing agreement with China's Sino Biopharmaceutical, paying $358 million upfront for a six‑program option covering preclinical antibody‑drug conjugates an…